Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013: Featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 10, 2012, Pages 1211-1219

  Anderson, Kenneth C ^a   Alsina, Melissa ^b   Bensinger, William ^c   Biermann, J Sybil ^d   Cohen, Adam D ^e   Devine, Steven ^f   Djulbegovic, Benjamin ^b   Faber, Edward A ^g   Gasparetto, Christine ^h   Hernandez Ilizaliturri, Francisco ⁱ   Huff, Carol Ann ^j   Kassim, Adetola ^k   Krishnan, Amrita Y ^l   Medeiros, Bruno C ^m   Meredith, Ruby ⁿ   Raje, Noopur ^o   Schriber, Jeffrey ^p   Singhal, Seema ^q   Somlo, George ^l   Stockerl Goldstein, Keith ^r   Treon, Steven P ^a   Tricot, Guido ^s   Weber, Donna M ^p   Yahalom, Joachim ^t   Yunus, Furhan ^u   Kumar, Rashmi ^v   Shead, Dorothy A ^v   more..

^a Da na Farber Brigham and Women s Cancer Center   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g NEBRASKA MEDICAL CENTER   (United States)

^h DUKE CANCER INSTITUTE   (United States)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k VANDERBILT INGRAM CANCER CENTER   (United States)

^l CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^m STANFORD CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^o MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^p UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^q NORTHWESTERN UNIVERSITY   (United States)

^r BARNES JEWISH HOSPITAL   (United States)

^s UNIVERSITY OF UTAH   (United States)

^t MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^u UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^v National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; DULOXETINE; EVEROLIMUS; FLUDARABINE; GABAPENTIN; IMMUNOGLOBULIN M; OFATUMUMAB; PARAPROTEIN; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

AGE; ALOPECIA; AUTONOMIC NEUROPATHY; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW BIOPSY; CANCER GRADING; CANCER INCIDENCE; CANCER SURVIVAL; CYTOPENIA; DRUG CYTOTOXICITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EVENT FREE SURVIVAL; FOLLOW UP; HERPES ZOSTER; HUMAN; INFECTION; LUNG TOXICITY; MONOTHERAPY; MULTIPLE MYELOMA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; SENSORY NEUROPATHY; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

EID: 84870983649     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0128     Document Type: Review

References (32)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:110-115.
2. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
3. Swerdlow SH, Berger F, Pileri SA, et al. Lymphoplasmacytic lymphoma. In: Swerdlow SH, Campo, E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: IARC Press; 2008:194.
4. Sekhar J, Sanfilippo K, Zhang Q, et al. Waldenstrom macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005. Leuk Lymphoma 2012;53:1625-1626.
5. Fonseca R, Hayman S. Waldenstrom macroglobulinaemia. Br J Haematol 2007;138:700-720.
6. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:116-120.
7. Treon SP. How I treat Waldenstrom macroglobulinemia. Blood 2009;114:2375-2385.
8. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1570-1575. (Pubitemid 46733084)
9. Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia. Am J Hematol 2010;85:670-674.
10. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009;27:3830-3835.
11. Chen C, Kouroukis CT, White D, et al. Bortezomib in relapsed or refractory Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009;9:74-76.
12. Rummel MJ, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with Waldenstrom's macroglobulinemia: first interim results of a randomized phase III study of the Study Group Indolent Lymphomas (StiL) [abstract]. Presented at the 5th International Workshop on Waldenstrom's macroglobulinemia; October 15-18, 2008; Stockholm, Sweden. Abstract 139.
13. Treon SP, Hanzis CA, Ioakimidis LI, et al. Clinical characteristics and treatment outcome of disease-related peripheral neuropathy in Waldenstrom's macroglobulinemia (WM) [abstract]. J Clin Oncol 2010;28(15 Suppl):Abstract 8114.
14. Benedetti L, Briani C, Grandis M, et al. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst 2007;12:102-107. (Pubitemid 46906332)
15. Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009;65:286-293.
16. Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003;74:485-489. (Pubitemid 36379372)
17. Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 2006;107:3442-3446.
18. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009;27:120-126.
19. Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004;101:2593-2598. (Pubitemid 39532289)
20. Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 2004;15:1481-1483. (Pubitemid 39409737)
21. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007;13:3320-3325. (Pubitemid 46944918)
22. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006;24:2105-2112. (Pubitemid 46622122)
23. Treon S, Tripsas C, Ioakimidis L, et al. Prospective, multicenter study of the mTOR inhibitor everolimus (RAD001) as primary therapy in Waldenstrom's macroglobulinemia [abstract]. Presented at the 53rd ASH Annual Meeting and Exposition; December 10-13, 2011; San Diego, California. Abstract 2951.
24. Varghese AM, Rawstron AC, Ashcroft AJ, et al. Assessment of bone marrow response in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009;9:53-55.
25. Treon SP, Merlini G, Morra E, et al. Report from the Sixth International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11:68-73.
26. Agathocleous A, Rohatiner A, Rule S, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia. Br J Haematol 2010;151:346-353.
27. Ghobrial IM, Matous J, Padmanabhan S, et al. Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia [abstract]. J Clin Oncol 2009;27(15 Suppl):Abstract 8535.
28. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 2005;90:1655-1658. (Pubitemid 41814990)
29. Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1422-1428.
30. Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11:133-135.
31. Ghobrial IM, Gertz MA, LaPlant B, et al. A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory waldenstrom's macroglobulinemia [abstract]. Blood 2009;114:Abstract 587.
32. Furman RR, Eradat H, Switzky JC, et al. A phase II trial of ofatumumab in subjects with Waldenstrom's macroglobulinemia [abstract]. Blood 2010;116:Abstract 1795.